US CDC panel endorses Pfizer booster shot for elderly, high-risk people

A US CDC advisory panel on Thursday endorsed booster doses of the Pfizer-BioNTech COVID-19 vaccine for Americans aged 65 and older and some adults with certain high risk conditions

Pfizer Vaccine, Coronavirus vaccine
Photo: Shutterstock
ANI US
1 min read Last Updated : Sep 24 2021 | 8:56 AM IST

A U.S. Centers for Disease Control and Prevention (CDC) advisory panel on Thursday endorsed booster doses of the Pfizer-BioNTech COVID-19 vaccine for Americans aged 65 and older and some adults with certain high risk conditions.

The panel voted 15-0 to recommend a booster dose for Americans age 65 and older and people in long term care facilities. It also fully recommended giving a single booster dose to people between the ages of 50 and 64 with certain high risk conditions, by a vote of 13-2.

On Wednesday, the Food and Drug Administration approved Pfizer boosters for people aged 65 and older or at high-risk. The extra dose would be given once they are at least six months past their last Pfizer shot.

CDC Director Rochelle Walensky is expected to accept the panel's endorsement shortly.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :PfizerCoronavirus VaccineUnited States

First Published: Sep 24 2021 | 8:56 AM IST

Next Story